Vireo Growth (VREOF) Short term Debt (2020 - 2026)

Vireo Growth (VREOF) posted Short term Debt of $1.3 million for Q1 2026, down 92.02% sequentially from $16.3 million in Q4 2025.

Vireo Growth (VREOF) Short term Debt (2020 - 2026) Analysis & Trends

Vireo Growth has reported Short term Debt for 7 years, with the latest figure at $1.3 million in Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (changed N/A YoY) and the FY2025 annual result came in at $16.3 million, up 1711.11% from the prior year.
Short term Debt fell to $1.3 million in Q1 2026 per VREOF's latest filing, from $16.3 million in the prior quarter.
Over five years, Short term Debt peaked at $61.5 million in Q2 2024 and troughed at $900000.0 in Q4 2024.
A 5-year average of $26.8 million and a median of $16.0 million in 2025 frame the typical range for Short term Debt.
The widest YoY moves for Short term Debt: up 1896.6% in 2024, down 98.51% in 2024.
Over 5 years, Short term Debt stood at $11.8 million in 2022, then soared by 411.21% to $60.2 million in 2023, then sank by 98.51% to $900000.0 in 2024, then surged by 1711.11% to $16.3 million in 2025, then tumbled by 92.02% to $1.3 million in 2026.
According to Business Quant data, Short term Debt over the past three periods registered $1.3 million, $16.3 million, and $15.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.98 Bn	43.02 Bn	-
2	Teva Pharmaceutical Industries	43.28 Bn	39.62 Bn	2.15 Bn
3	Zoetis	31.79 Bn	30.11 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.69 Bn	22.89 Bn	5.10 Bn
5	United Therapeutics	22.25 Bn	19.58 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.58 Bn	15.19 Bn	935.80 Mn
8	Elanco Animal Health	11.87 Bn	11.34 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-
10	Vireo Growth	487.39 Mn	345.09 Mn	95.30 Mn

Download Data